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Introduction
Highly active antiretroviral therapy (HAART) has markedly increased life expectancy among
persons infected with HIV. As HIV-infected persons age, chronic diseases like atherosclerosis
have become increasingly important in their healthcare. Use of HAART has been linked to
dyslipidemia and insulin resistance, well-established risk factors for atherosclerosis.[1-3]
Individuals infected with HIV may also be at risk for vascular disease secondary to direct viral
effects which induce chronic immune activation leading to increased expression of pro-
inflammatory mediators by activated T cells and macrophages within the vasculature.[4,5]
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Several pro-inflammatory cytokines and chemokines associated with HIV infection are linked
to atherosclerosis, and may participate in vascular dysfunction in infected individuals.
Monocyte chemoattractant protein-1 (MCP-1/CCL2) plays a crucial role in the pathogenesis
of atherosclerosis, attracting monocytes into the arterial intima where they differentiate into
macrophages, accumulate lipoproteins and become lipid-laden foam cells.[6] We previously
demonstrated that human arterial smooth muscle cells (SMC) express the chemokine receptors
CXCR4 and CCR5, and that HIV-infected SMC are themselves a source of MCP-1/CCL2, and
have shown that MCP-1/CCL2 induces tissue factor, a major contributor to thrombosis
associated with plaque rupture, in vascular SMC.[7,8] These findings suggest that HIV
infection promotes an inflammatory response in the vessel wall and may thereby accelerate
atherosclerosis.
Studies examining relationships of HIV infection and HAART with carotid artery intima-media
thickness (IMT) as a surrogate marker for atherosclerosis have had conflicting results. Some
have found little association with HIV infection or specific classes of antiretrovirals, whereas
others have reported greater IMT among HIV-infected subjects but no association with
antiretrovirals, and yet others have shown greater IMT associated with protease inhibitors (PIs).
[9-12] Carotid artery ultrasound enables imaging of exophytic plaque on the carotid artery wall
and measures IMT. However ultrasound may be unable to detect early atheromatous changes,
cannot image the adventitial layer to gauge outward remodeling, and is unable to assess
atherosclerosis in the thoracic aorta. Magnetic resonance imaging (MRI) is a noninvasive
imaging modality that detects early atheroma formation and allows more global assessment of
vascular structure, including the aorta.[13,14]
To assess whether HIV infected individuals have increased serum markers of inflammation
and increased atherosclerosis plaque burden, we measured MCP-1/CCL2 levels and performed
MRI of the thoracic aorta and carotid arteries in a well-characterized sample of HIV-infected
and demographically similar uninfected individuals.
Methods
Study Participants and Design
We performed a cross-sectional analysis of MCP-1/CCL2 levels and thoracic aorta and carotid
artery vessel wall parameters, as measured by high-resolution MRI, among participants in two
parallel prospective observational studies of aging among men (CHAMPS study) and women
(Menopause Study) who were either HIV-infected or at risk for infection because of injection
drug use or high-risk sex (sex with a drug user; exchanging sex for money/drugs; unprotected
sex with a man who has sex with men; or ≥5sexual partners in the past five years). Participants
were recruited from the community in the Bronx, New York between September 2001 and July
2003. The study designs have been previously described in detail.[15,16] In brief, participants
attended semi-annual research visits for standardized interviews, blood analysis, measurement
of weight, height, and blood pressure, and carotid ultrasound to measure IMT.
From April 2005 to December 2006, participants with common carotid artery IMT of ≥0.7 mm
(the minimum thickness required for optimal resolution of the vessel wall on MRI) were
enrolled in a sub-study using MRI to characterize the vessel wall and detect atherosclerotic
plaque in the carotid arteries and thoracic aorta. Participants eligible for the MRI sub-study
were ≥45 years old and were not taking lipid-lowering medications. Individuals with metallic
implants or claustrophobia, and women who were pregnant, were excluded. The study was
approved by Institutional Review Boards at Montefiore Medical Center, Albert Einstein
College of Medicine, and Mount Sinai School of Medicine. All participants gave written
informed consent.
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Standardized semi-annual interviews collected data on socio-demographics, medical history,
HIV disease status, antiretroviral and other medications, physical activity, past/current illicit
drug use (frequency/route of cocaine and heroin use), and cigarette smoking. Hypertension
was defined as systolic blood pressure ≥130 mm Hg/diastolic blood pressure ≥85 mm Hg, using
the average of two measurements taken while the participant was sitting. Participants with
known hypertension and current use of anti-hypertensive medications were defined as
hypertensive regardless of measured blood pressure. Limb and trunk fat were measured by
dual X-ray absorptiometry (DEXA) scans using a GE Lunar Prodigy densitometer, Version
6.8 (Madison, Wisconsin, USA).
Assays
Blood was obtained for T-lymphocyte subset assays, HIV-1 viral load, MCP-1/CCL2 levels,
hepatitis C virus antibody and RNA, and lipoprotein levels. Plasma was separated within 20
minutes of collection and stored at -70°C. Previously unthawed specimens were used for
MCP-1/CCL2 assays. Levels of MCP-1/CCL2 were measured by sandwich enzyme-linked
immunosorbent assay (Duoset ELISA, R & D Systems, Minneapolis, MN) with a sensitivity
of 4 pg/mL. Blood was analyzed for CD4+ lymphocyte studies using flow cytometry and for
HIV viral load by b-DNA assay (lower limit of detection 75 copies/ml). HIV serology was
repeated at every visit for HIV-seronegative participants. Hepatitis C virus antibody testing
was performed using enzyme immunoassay (ELISA 3.0, Ortho Diagnostic Systems, Rochester,
NY). For HCV seropositive participants, HCV RNA was quantified by VERSANT HCV RNA
assay (Bayer Corporation, Tarrytown, NY, lower limit of detection 615 IU/mL).
Lipoprotein levels were assayed by routine laboratory techniques using blood drawn following
a 10-12 hour overnight fast.[17] Low-density cholesterol (LDL-C) levels were measured
directly (Olympus Diagnostics, Olympus America Inc., Melville, NY). Participants without
known diabetes underwent oral glucose tolerance testing, using a 75-g glucose beverage.
Impaired glucose tolerance and diabetes mellitus were defined using American Diabetes
Association criteria.[18]
Carotid Ultrasound
High-resolution B-mode carotid ultrasound scans were performed by a single technician with
the participant supine. A Phillips ATL HDI 5000 ultrasound unit (Advanced Technology
Laboratories, Bothell, Washington, USA) was used, with a linear L 7-4 broad band transducer
and software optimized for carotid examinations. Right and left common carotid artery IMT
measurements were obtained from the region of maximal wall thickness, within the distal
10mm of each common carotid artery. Three measurements of the far vessel wall were obtained
on transverse cross-sectional views by a single radiologist using the instrument's electronic
caliper, each measurement taken perpendicular to the curvature of the vessel wall. Three
longitudinal views were also obtained. Mean IMT for each vessel was calculated by averaging
the 3 measurements. The technician and radiologist were blinded to participants' HIV status.
MR Imaging
Non-contrast-enhanced MRI was performed on a 1.5T whole body MR system (Siemens
Sonata, Erlangen Germany). A custom-built four-element phased array coil was used for
carotid imaging. The six-element spine array and a two-channel anterior body coil were used
for aortic imaging. After localization with a fast-gradient-echo sequence, all images were
obtained by rapid extended coverage, double-inversion recovery (i.e., black-blood) turbo-spin-
echo technique.[19] Carotid and abdominal aorta images were acquired without cardiac
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triggering and free breathing; thoracic aorta images were acquired with ECG gating and breath
hold where possible. Proton density (PD), T1 and T2 weighted images were acquired.
For carotid artery imaging, 24 transverse images centered at the carotid bifurcation were
obtained with the following parameters: repetition time 2130ms/ 2130ms/900ms (PD/T2/ T1
images); echo time, 5.6/56/5.6ms (PD/T2/ T1 images); field of view, 12 cm; slice thickness,
3mm; 10% inter-slice gap; acquisition matrix, 256 x 256; no phase wrap; number of signal
averages 2/4/3 (PD/T2/ T1 images); turbo factor (echo train length), 15/15/3 (PD/T2/ T1
images); receiver bandwidth, 488 Hz/pixel; no zero filling. 12 slices were acquired
simultaneously with 4 dark-blood blocks. Inversion time was 157 ms. A chemical shift
suppression pulse was used to suppress signal from fat. For the thoracic aorta, 16 to 32
transverse images were obtained from the origin of the left subclavian artery to the diaphragm.
Imaging parameters were similar to carotid imaging, except: ECG gating was used; repetition
time, 2RR intervals/ 2RR intervals/ 1RR interval (PD/T2/ T1 images); slice thickness, 5mm;
16 slices acquired simultaneously with 4 dark-blood blocks (above the level of the ventricles);
4 slices acquired simultaneously with 2 dark-blood blocks for mid-ventricular images; turbo
factor, 31; inversion time, 450ms. The total examination lasted approximately 60 minutes.
The MR images were transferred to a dedicated computer for further planimetric analysis.
Vessel wall dimensions were calculated by semi-automatic tracing, using computer-assisted
morphometric analysis of cross-sectional MR images (Image Pro-Plus, Media Cybernetics,
Carlsbad, CA). The tracing tool works by following an edge of significant contrast. Minimal,
maximal and mean vessel wall thickness (VWT) and vessel wall area (VWA) were measured.
Measurements were performed blinded to the participants' HIV status.
Data Analysis
Statistical analyses were performed using STATA® (Version 9, StataCorp, College Station,
TX) and SPSS® (base 15.0, SPSS Inc., Chicago, IL) software. Univariate analyses were
performed using Student's t-test or Mann-Whitney test, as appropriate. Regression analysis
examined linear associations of MCP-1/CCL2 with HIV viral load, CD4+ cell count and vessel
wall parameters, adjusting for age, body mass index (BMI) and current cigarette smoking.
Linear regression models were constructed for thoracic aorta and common carotid artery mean
VWT and VWA, measured by MRI. Carotid artery measurements used were the average of
mean values for the left and right common carotid arteries. The outcome variables were log-
transformed to meet normality criteria for linear regression. Covariates examined in
multivariate analyses were HIV and viral load status, PI use, MCP-1/CCL2, age, race/ethnicity,
hypertension, diabetes mellitus/impaired glucose tolerance, LDL-C, HDL-C, total
cholesterol:HDL-C ratio, BMI, cigarette smoking, physical activity, trunk and limb fat, and
HCV status. Interaction terms were tested and model fit examined. Based on data from the
Framingham Heart Study offspring cohort, where MRI measured atherosclerotic plaque in
asymptomatic adults, a sample size of 84 participants undergoing MRI would be necessary to
achieve 90% power to detect a difference in vessel wall thickness between high- and low-risk




One hundred ninety-one participants had carotid artery IMT of 0.7 mm or higher. Of these, 14
were on lipid-lowering medications and were therefore not eligible for this sub-study. All
eligible participants had phlebotomy to measure MCP-1/CCL2. The first 120 of 177 eligible
participants presenting for Menopause and CHAMPS study visits were screened for
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participation in MRI testing. Of these, 36 had metallic implants or claustrophobia and were
therefore excluded from undergoing MRI. A total of 177 participants are therefore included in
this analysis, 84 of whom had MRI testing. The 84 MRI participants did not differ from the
rest of the sample with respect to hypertension, diabetes mellitus, LDL-C, total
cholesterol:HDL-C ratio, or cigarette smoking, nor in terms of the proportion that had
detectable HIV viremia or currently used PI. A smaller proportion of the MRI group was male
compared to the overall sample, largely because a higher proportion of men were ineligible for
MRI due to retained metal from gunshot wounds.
Participants' characteristics
Of 177 participants, 98 (55%) were HIV-infected, of whom 60 (61%) had detectable HIV
viremia (Table 1). Most (81%) of HIV-infected participants were antiretroviral-experienced
and 67% were currently taking HAART, 48% of whom were taking PIs. Among PI-users the
median duration of PI use was 66 months (IQR 42, 98) and 77% were on a ritonavir-boosted
regimen. Antiretroviral use differed between HIV-infected participants with undetectable viral
load and those with detectable viremia (p =.04). Of participants with detectable HIV viremia,
43% were not currently using antiretrovirals (vs. 16% of those with undetectable viral load)
and 25% were antiretroviral-naive.
The majority of participants (68% of HIV-infected and 52% of HIV-uninfected) were Black.
Differences in race/ethnicity by HIV and viral load status approached statistical significance
(p =.05). Limb fat was highest among HIV-uninfected participants (p =.04); differences in
trunk fat and BMI were not statistically significant. Compared to uninfected participants, HIV-
infected participants had lower HDL-C (p =.01) but similar total cholesterol, LDL-C and
triglyceride levels. Cigarette smoking was most prevalent among uninfected participants (p =.
02), however the proportion smoking ≥1 pack per day did not differ by HIV or viral load status.
Rates of hypertension and impaired glucose tolerance/diabetes mellitus were similar.
MCP-1/CCL2 levels
As shown in Table 1, mean MCP-1/CCL2 levels did not differ significantly between groups
by HIV and viral load status (p =.71). However, analysis of linear relationships of MCP-1/
CCL2 with HIV viral load among the HIV-infected participants (Figure 1A) showed a positive
association, which remained significant after adjusting for age, BMI and current cigarette
smoking (p =.02). Analysis of CD4+ cell count with MCP-1/CCL2 (Figure 1B) suggested a
negative linear relationship, however this association did not reach statistical significance (p
=.07). There was a positive association of MCP-1/CCL2 with both thoracic aorta VWA (p =.
01) and VWT (p <.01), after adjusting for age, BMI and current cigarette smoking (Figure 2).
There was no significant association of MCP-1/CCL-2 with carotid artery parameters.
Vessel wall parameters
Univariate Analysis—Upon univariate analysis, HIV infection was associated with higher
mean thoracic aorta VWA (1.17 mm2 among HIV-infected vs. 1.08, p =.049). Associations of
thoracic aorta VWT with HIV status (mean =1.56 mm among HIV-infected vs. 1.51, p =.07)
did not reach statistical significance. There was no association of any vessel wall parameter
with viral load or antiretroviral group.
Other factors associated with thoracic aorta VWA on univariate analysis were male gender
(p <.01), older age (p =.01), and smoking one or more packs of cigarettes/day (p =.03). Having
an LDL-C ≥130 mg/dL had a borderline significant association with higher carotid artery VWA
(p =.05). There was no association of any of the vessel wall parameters with hypertension,
impaired glucose tolerance/diabetes, BMI, or hepatitis C status on univariate analysis.
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Multivariate Analysis—Multivariate analyses of factors associated with vessel wall
parameters are shown in Tables 2A and 2B. After adjusting for gender, cigarette smoking, PI
use, MCP-1/CCL2, LDL-C, and total cholesterol:HDL-C ratio (Table 2A), being HIV infected
was independently associated with having greater mean thoracic aorta VWA and VWT. Being
HIV-infected was not significantly associated with carotid artery VWA or VWT. Higher
MCP-1/CCL2 levels were independently associated with higher thoracic aorta VWA and
VWT, but not with carotid artery measurements. Protease inhibitor use was not associated with
any of the vessel wall parameters. Other factors independently associated with thoracic aorta
VWA were male gender and cigarette smoking. Cigarette smoking was also associated with
higher thoracic aorta VWT.
Inclusion of HIV viral load status in the multivariate analysis (Table 2B) showed that compared
to being uninfected, being HIV infected with detectable viremia was independently associated
with having greater mean thoracic aorta VWA and VWT. Compared to being uninfected, being
HIV-infected with undetectable viral load was associated with increased thoracic aorta VWA,
but not with VWT. Relationships between other covariates and outcome variables remained
similar to those found in the models that included HIV status but not viral load. Race/ethnicity,
age, limb and trunk fat, physical activity level, current cocaine use and hepatitis C status were
explored in the multivariate models but were not significantly associated with any of the vessel
wall parameters and did not alter relationships of other covariates with the outcome.
Discussion
In this study of a well-characterized group of HIV-infected participants and a demographically
similar, high-risk, uninfected comparison group, HIV-infected individuals with higher viral
load had higher MCP-1/CCL2 levels, which correlated with greater thoracic aorta
atherosclerotic burden. There was also a positive linear relationship between HIV viral load
and MCP-1/CCL2, suggesting that the amount of circulating virus may affect MCP-1/CCL2
levels. Although not statistically significant, there was a trend towards a negative correlation
of CD4+ cell count with MCP-1/CCL2. Interestingly, even after adjustment for HIV status and
viremia, MCP-1/CCL2 remained independently associated with atherosclerotic burden,
suggesting that higher MCP-1/CCL2 levels may contribute additional risk for atherosclerosis,
even after accounting for the effect of HIV infection, PI use, and traditional cardiovascular risk
factors.
Weiss et al reported similar associations between HIV viremia and MCP-1/CCL2, showing
higher MCP-1/CCL2 levels in HIV-infected individuals with higher viral loads compared with
those with undetectable virus and healthy controls.[21] Similarly, in a study of 36 HIV-infected
subjects, of whom 18 were viremic, investigators reported higher MCP-1/CCL2 mRNA
expression and serum levels among viremic compared to aviremic subjects.[22] Coll et al have
reported increased atherosclerosis in HIV-infected patients who have the MCP-1-2518 allele
and found a correlation between MCP-1/CCL2 and IMT among HIV- infected patients who
also had clinical evidence of lipodystrophy.[23][24]
Our analysis, adjusted for traditional cardiovascular risk factors, revealed greater thoracic aorta
VWA and VWT associated with detectable HIV viremia. Having HIV infection, in the absence
of detectable viremia, was associated with having greater VWA but not with increased VWT.
Of note, corresponding analysis of carotid artery parameters revealed no significant
associations with HIV infection or viral load status. It is possible that this reflects a differential
impact of HIV infection and associated inflammation on different vascular sites. Both the aorta
and the coronary arteries are derived from the embryonic mesoderm, while the carotid arteries
develop from the ectoderm.[25] In addition, the magnitude of shear stress in the aorta differs
considerably from that of the carotid arteries, potentially contributing to a differential effect
Floris-Moore et al. Page 6













of inflammation on the vascular endothelium in these two locations.[26] Evidence suggests
that the endothelial cell response to inflammatory stimuli is modulated by blood flow, and
increased fluid shear stress has been shown to lead to increased MCP-1/CCL2 gene activation.
[27,28] Our finding of associations of HIV/viral load status and MCP-1/CCL2 concentrations
with thoracic aorta but not carotid artery parameters indicates the need for further investigation
of mechanisms by which HIV infection promotes atherosclerosis, and perhaps different
screening modalities for detecting subclinical vascular disease in HIV-infected individuals.
Other studies of subclinical atherosclerosis in the HIV-infected population have shown variable
associations with HIV infection and antiretroviral therapy.[9,10,12] In a prospective cohort
study of participants matched for age, sex, race, cigarette smoking, blood pressure and
menopausal status, Currier et al reported no association of IMT with HIV infection or PIs, but
found instead that age, BMI, and HDL-cholesterol predicted IMT.[9] In another longitudinal
study that assessed both HIV-infected and uninfected participants, Hsue et al reported higher
baseline carotid IMT and more rapid 1-year progression among HIV-infected patients versus
age-matched controls, but no associations with PIs. In contrast, Johnsen et al found no
association of IMT with HIV status, but increased IMT in HIV-infected subjects taking PIs
versus those not on PIs.[11]
Many of these studies have not, however, included measures of inflammation and none have
assessed atherosclerosis in the thoracic aorta. The use of MRI, which allows imaging of the
thoracic aorta, is a major strength of our study. Although not in widespread clinical use for
cardiovascular risk assessment, MRI is well-validated in cardiovascular research as a sensitive
and reliable measure of atherosclerosis.[13,14,29] The fact that MRI allows visualization of
the full-thickness of the vessel wall, as opposed to being limited to the intima and media, may
be particularly advantageous when assessing atherosclerosis in the setting of HIV-infection.
There is evidence suggesting that the mechanism of vascular disease in HIV-infected
individuals may differ somewhat from typical atherosclerotic plaque formation. Early in the
HIV epidemic, autopsies of young HIV-infected patients found a distinct arteriopathy with
lesions intermediate in appearance between typical atherosclerosis and lesions seen with
chronic rejection of cardiac transplants.[30] More recently, Regina et al reported two cases of
HIV-infected patients who underwent surgery for carotid artery stenosis, describing extensive
inflammatory infiltration of the vascular wall without typical atheromatous plaques.[31]
Our study is limited by its cross-sectional design. In addition, the relatively small number of
participants with MRI results precludes a more detailed analysis of the impact of viral load and
CD4+ cell count within the HIV-infected group. This study does, however, offer the advantage
of including an HIV-uninfected comparison group with similar background cardiovascular
risk, allowing us to better assess the impact of HIV infection and antiretroviral therapy.
Although race/ethnicity was not found to be associated with vessel wall parameters in this
study, the majority of participants in our study sample were Black, which may limit ability to
generalize our findings to other HIV-infected populations with a different racial/ethnic
composition.
In summary, our study finds that higher HIV viral load correlates with higher MCP-1/CCL2
levels, and shows an association of HIV infection and viral load status with atherosclerotic
burden in the thoracic aorta. These findings highlight the need for further investigation focusing
not only on traditional cardiovascular risk, but also on immunologic factors as potential
contributors to atherosclerosis in the HIV-infected population.
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Relationship of monocyte chemoattracted protein-1/chemokine (C-C motif) ligand 2 with
HIV-1 viral load and CD4+ cell count among HIV-infected participants. This figure shows the
relationship of MCP-1/CCL2 with HIV-1 viral load (a) and CD4+ cell count (b) among HIV-
infected participants. Dashed line represents linear prediction from regression of MCP-1/CCL2
on viral load (P=0.02) and CD4+ cell count, respectively (P=0.07), with 95%Cls shown in
gray. *HIV-1 viral load was log-transformed to meet criteria for linear regression. CCL2,
chemokine (C-C motif) ligand 2; CI, confidence interval; MCP-1, monocyte chemoattractant
protein-1.
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Relationship of thoracic aorta mean vessel wall area and mean vessel wall thickness with
monocyte chemoattractant protein-1/chemokine (C-C motif) ligand 2. The figure shows
relationship of thoracic aorta mean VWA (a) and mean VWT (b) with MCP-1/CCL2. Dashed
line represents linear prediction from regression on MCP-1/CCL2 of VWA (P=0.01) and VWT
(P<0.01), respectively, with 95% CIs shown in gray. CCL2, chemokine (C-C motif) ligand 2;
CI, confidence interval; MCP-1, monocyte chemoattractant protein-1; VWA, vessel wall area;
VWT, vessel wall thickness.
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